This review discusses evidence in support of the combined use of dabrafenib and trametinib which inhibit BRAF and MEK kinases, respectively, in the treatment of BRAFV600 mutations and Stage III-IV metastatic melanoma.
Independent expert commentary provided by Dr. Victoria Atkinson who is a Senior Staff Specialist Medical Oncologist at the Princess Alexandra Hospital since 2007 and Visiting Medical Oncologist at Greenslopes Private Hospital since 2011.
Please login below to download this issue (PDF)